ARTICLE | Product Development
AnaptysBio looks ahead to other indications after Phase II miss in palmoplantar pustulosis
March 9, 2021 12:44 AM UTC
Following a Phase II miss for imsidolimab to treat palmoplantar pustulosis, AnaptysBio will look ahead to five other indications for the IL-36R antagonist.
The company plans to bring imsidolimab (ANB019) into Phase III testing mid-year for generalized pustular psoriasis (GPP), where IL-36 signaling has a clearer role in driving disease. ...
BCIQ Company Profiles